Furthermore, recent retrospective analyses underscored the survival benefits of a TACE-lenvatinib-PD-(L)1 inhibitor regimen vs. the TACE-lenvatinib combination in patients with advanced or unresectable HCC (38, 39). Here, CD274 is linked to hepatocellular carcinoma.